基因治疗市场规模、份额、成长分析（按基因类型、按治疗类型、按载体类型、按递送方式、按给药途径、按应用、按最终用户、按地区）- 行业预测，2025 年至 2032 年

2023 年全球基因治疗市场规模价值为 65 亿美元，预计将从 2024 年的 77.4 亿美元成长到 2032 年的 313.4 亿美元，预测期内（2025-2032 年）的复合年增长率为 19.1%。

由于医疗成本不断上涨、医疗设施日益先进以及报销选择不断增加，全球基因治疗市场呈上升趋势。然而，基因治疗药物的高成本可能在未来几年内在一定程度上阻碍市场成长。基因治疗是一种透过以功能性基因取代缺陷基因来治疗多种疾病（包括血液疾病、癌症、慢性病和感染疾病）的创新治疗方法。这些是体细胞细胞株治疗，针对特定的体细胞来治疗爱滋病或帕金森氏症等疾病，以及生殖系基因治疗，影响生殖细胞株中的遗传 DNA。生物载体有助于治疗基因的传递，包括慢病毒和腺病毒等病毒载体，以及脂质体和质体等非病毒载体。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管格局
• 案例研究
• 技术分析

基因治疗市场规模（以基因类型划分）

• 市场概览
• 抗原
• 细胞激素
• 肿瘤抑制
• 自杀
• 不足
• 生长因子
• 受体
• 其他的

基因治疗市场规模（依治疗类型）

• 市场概览
• 基因静默疗法
• 细胞替代疗法
• 基因增强疗法
• 其他治疗方法

基因治疗市场规模（按载体类型）

• 市场概览
• 病毒载体
  • 逆转录病毒载体
  • AAV载体
  • 其他的
• 非病毒载体
  • 寡核苷酸载体
  • 其他的

基因治疗市场规模（以交付方式）

• 市场概览
• 体外
• 体内

基因治疗市场规模（依给药途径）

• 市场概览
• 静脉注射
• 皮下途径
• 其他的

基因治疗市场规模（按应用）

• 市场概览
• 肿瘤疾病
• 心血管疾病
• 感染疾病
• 血液学
• 罕见疾病
• 神经系统疾病
• 其他疾病

基因治疗市场规模（按最终用户划分）

• 市场概览
• 癌症研究所
• 医院
• 研究组织
• 其他的

基因治疗市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Krystal Biotech（USA）
• CRISPR Therapeutics（Switzerland）
• Intellia Therapeutics（USA）
• Beam Therapeutics（USA）
• Neurogene（USA）
• Prime Medicine（USA）
• Taysha Gene Therapies（USA）
• Verve Therapeutics（USA）
• Voyager Therapeutics（USA）
• Korro Bio（USA）
• Poseida Therapeutics（USA）
• MeiraGTx（USA）
• enGene（Canada）
• Editas Medicine（USA）
• uniQure（Netherlands）
• Sangamo Therapeutics（USA）
• Generation Bio（USA）
• Adverum Biotechnologies（USA）
• Benitec Biopharma（USA）

结论和建议

Global Gene Therapy Market size was valued at USD 6.5 billion in 2023 and is poised to grow from USD 7.74 billion in 2024 to USD 31.34 billion by 2032, growing at a CAGR of 19.1% during the forecast period (2025-2032).

The global gene therapy market is on an uptrend, driven by escalating healthcare costs, state-of-the-art healthcare facilities, and reimbursement options. However, the high cost of gene therapies may somewhat hinder market growth in the coming years. Gene therapy is an innovative treatment modality for various diseases, including blood disorders, cancer, chronic illnesses, and infections, by replacing faulty genes with functional ones. It encompasses two primary types: somatic gene therapy, which targets specific body cells to treat conditions like AIDS and Parkinson's, and germline gene therapy, which affects hereditary DNA in reproductive cells. Delivery of therapeutic genes is facilitated by biological vectors, including viral vectors like lentivirus and adenovirus, as well as non-viral options such as liposomes and plasmids.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gene Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Gene Therapy Market Segments Analysis

Global Gene Therapy Market is segmented by Gene Type, Therapy type, Vector type, Delivery Method, Route Of Administration, Application, End-user and region. Based on Gene Type, the market is segmented into Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth factors, Receptors and Others. Based on Therapy type, the market is segmented into Gene silencing therapy, Cell replacement therapy, Gene augmentation therapy and Other therapies. Based on Vector type, the market is segmented into Viral vector and Non-Viral Vector. Based on Delivery Method, the market is segmented into Ex-Vivo and In-Vivo. Based on Route Of Administration, the market is segmented into Intravenous Route, Subcutaneous Route and Others. Based on Application, the market is segmented into Oncological Disorders, Cardiovascular Diseases, Infectious Diseases, Hematology, Rare Diseases, Neurological Disorders and Other Diseases. Based on End-user, the market is segmented into Cancer Institutes, Hospitals, Research institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Gene Therapy Market

The global gene therapy market is experiencing significant growth, driven by swift innovations in gene editing technologies like CRISPR-Cas9. These cutting-edge techniques enhance the precision, effectiveness, and safety of genetic modifications, thereby accelerating the clinical development process and expanding treatment options for patients. Furthermore, the use of vector-based methods coupled with improved delivery systems is contributing to the industry's advancement. As a result, the combination of these factors is fostering an environment ripe for breakthroughs in gene therapy, ultimately leading to enhanced therapeutic outcomes and a broader range of solutions for various genetic disorders on a global scale.

Restraints in the Global Gene Therapy Market

The growth of the global gene therapy market is likely to face challenges stemming from various factors, including potential long-term risks, off-target effects, and a host of ethical and safety considerations. These issues could lead to hesitance among the public and regulatory bodies, resulting in a lack of acceptance for new therapies. Such skepticism may deter investment opportunities and impede overall market expansion, as concerns regarding genetic engineering persist. Therefore, overcoming these reservations is essential for fostering confidence in gene therapy developments and ensuring a sustainable trajectory for the industry in the coming years.

Market Trends of the Global Gene Therapy Market

The global gene therapy market is experiencing remarkable growth driven by rapid advancements in genetic research, the rise of innovative treatment methodologies, and an increasing understanding of gene-based therapies. A significant trend is the focus on rare hereditary disorders, as scientists identify genetic defects that underlie these conditions and develop corresponding gene therapies. This shift not only opens new avenues for treatment but also brings hope to patients with previously incurable diseases, fueling demand for targeted and precise therapies. Furthermore, regulatory advancements and increased investment in biotechnology are expected to propel market expansion, solidifying gene therapy's role in modern medicine.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technology Analysis

Global Gene Therapy Market Size by Gene Type & CAGR (2025-2032)

• Market Overview
• Antigen
• Cytokine
• Tumor Suppressor
• Suicide
• Deficiency
• Growth factors
• Receptors
• Others

Global Gene Therapy Market Size by Therapy type & CAGR (2025-2032)

• Market Overview
• Gene silencing therapy
• Cell replacement therapy
• Gene augmentation therapy
• Other therapies

Global Gene Therapy Market Size by Vector type & CAGR (2025-2032)

• Market Overview
• Viral vector
  • Retroviral vectors
  • AAV Vectors
  • Others
• Non-Viral Vector
  • Oligonucleotide Vectors
  • Others

Global Gene Therapy Market Size by Delivery Method & CAGR (2025-2032)

• Market Overview
• Ex-Vivo
• In-Vivo

Global Gene Therapy Market Size by Route Of Administration & CAGR (2025-2032)

• Market Overview
• Intravenous Route
• Subcutaneous Route
• Others

Global Gene Therapy Market Size by Application & CAGR (2025-2032)

• Market Overview
• Oncological Disorders
• Cardiovascular Diseases
• Infectious Diseases
• Hematology
• Rare Diseases
• Neurological Disorders
• Other Diseases

Global Gene Therapy Market Size by End-user & CAGR (2025-2032)

• Market Overview
• Cancer Institutes
• Hospitals
• Research institutes
• Others

Global Gene Therapy Market Size & CAGR (2025-2032)

• North America (Gene Type, Therapy type, Vector type, Delivery Method, Route Of Administration, Application, End-user)
  • US
  • Canada
• Europe (Gene Type, Therapy type, Vector type, Delivery Method, Route Of Administration, Application, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Gene Type, Therapy type, Vector type, Delivery Method, Route Of Administration, Application, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Gene Type, Therapy type, Vector type, Delivery Method, Route Of Administration, Application, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Gene Type, Therapy type, Vector type, Delivery Method, Route Of Administration, Application, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Krystal Biotech (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CRISPR Therapeutics (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intellia Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beam Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurogene (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Prime Medicine (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Taysha Gene Therapies (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Verve Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Voyager Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Korro Bio (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Poseida Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MeiraGTx (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• enGene (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Editas Medicine (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• uniQure (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Generation Bio (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adverum Biotechnologies (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Benitec Biopharma (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations